Drug General Information
Drug ID
D0H0ZV
Former ID
DNCL003383
Drug Name
MEDI7814
Indication Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10:J40-J44, J47] Phase 1 [523815]
Company
AstraZeneca
Target and Pathway
Target(s) Complement C5 Target Info Modulator [1572591]
KEGG Pathway Complement and coagulation cascades
Prion diseases
Pertussis
Staphylococcus aureus infection
Herpes simplex infection
Systemic lupus erythematosus
Reactome Activation of C3 and C5
Peptide ligand-binding receptors
G alpha (i) signalling events
Regulation of Complement cascade
WikiPathways Complement Activation, Classical Pathway
Human Complement System
Spinal Cord Injury
Allograft Rejection
GPCR ligand binding
GPCR downstream signaling
Complement cascade
References
Ref 523815ClinicalTrials.gov (NCT01544361) A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers. U.S. National Institutes of Health.
Ref 1572591Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.